AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2890423
Drug: ZK 91
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 91 296 and ZK 95 962 (high doses, intravenous)
Trial: 2890423
Drug: ZK 93
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93 426 in combination with lormetazepam
Trial: 23569138
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet with keto acid supplementation (0.1 g/kg IBW per day)
Trial: 19214941
Drug: BGP-15 200
RxNorm normalized name: Bgp-15 free base
DrugBank: NP-51 (DB16995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGP-15 200 mg
Trial: 19214941
Drug: BGP-15 400
RxNorm normalized name: Bgp-15 free base
DrugBank: NP-51 (DB16995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGP-15 400 mg
Trial: 17080881
Drug: Panavia F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panavia F 2.0 (P) at 20 g/mm²
Trial: 17080881
Drug: Panavia F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panavia F 2.0 (P) at 40 g/mm²
Trial: 17080881
Drug: RelyX Unicem
RxNorm normalized name: Hippeastrum puniceum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RelyX Unicem (RU) at 20 g/mm²
Trial: 17080881
Drug: RelyX Unicem
RxNorm normalized name: Hippeastrum puniceum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RelyX Unicem (RU) at 40 g/mm²
Trial: 17080881
Drug: Maxcem (M)
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxcem (M) at 20 g/mm²
Trial: 17080881
Drug: Maxcem (M)
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxcem (M) at 40 g/mm²
Trial: 11712625
Drug: Citalopram (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (specific dosage not mentioned)
Trial: 10487593
Drug: PGG-glucan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGG-glucan 0.5 mg/kg
Trial: 10487593
Drug: PGG-glucan 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGG-glucan 1.0 mg/kg
Trial: 7639438
Drug: Slow-release sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it)
Trial: 2654788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of recombinant interferon (rIFN) alpha‐2 and chemotherapy
Trial: 2654788
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (VMCP)
Trial: 19205
Drug: Tolmetin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolmetin (1.6 g daily)
Trial: 19205
Drug: Alclofenac (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alclofenac (4 g daily)
Trial: 31064847
Drug: AT1413 bispecific
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1413 bispecific T-cell-engaging antibody (bTCE)
Trial: 23822797
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (25 μg/day as cholecalciferol tablets)
Trial: 21219433
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of rapid-acting insulin (mean 7.3±0.2 units)
Trial: 21219433
Drug: 75% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% dose of rapid-acting insulin (mean 5.4±0.1 units)
Trial: 21219433
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose of rapid-acting insulin (mean 3.7±0.1 units)
Trial: 21219433
Drug: 25% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% dose of rapid-acting insulin (mean 1.8±0.1 units)
Trial: 19968379
Drug: MoodGYM online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoodGYM online cognitive behavioral therapy program
Trial: 17010221
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg G115
Trial: 17010221
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg G115
Trial: 17010221
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg ginseng and 30 mg saccharin)
Trial: 17010221
Drug: Ginseng (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (200 mg ginseng and 30 mg saccharin)
Trial: 17010221
Drug: Placebo-glucose (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-glucose (0 mg ginseng and 25 g oral glucose)
Trial: 17010221
Drug: Ginseng-glucose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng-glucose (200 mg ginseng and 25 g oral glucose)
Trial: 15463873
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate (Immunocal, 10 g twice a day)
Trial: 3549844
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin supplementation
Trial: 30269642
Drug: Phentermine 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 45 mg
Trial: 30269642
Drug: Phentermine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 90 mg
Trial: 20157323
Drug: Taranabant 4
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 4 mg
Trial: 22722508
Drug: Taranabant 20
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 20 mg
Trial: 22722508
Drug: Taranabant (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant (various doses)
Trial: 22722508
Drug: Phentermine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine (various doses)
Trial: 19900726
Drug: NT-pro-BNP ≥180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-pro-BNP ≥180 pg/ml
Trial: 18272335
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (300 mg/d)
Trial: 14595277
Drug: Tongue suspension
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue suspension
Trial: 8683249
Drug: GM‐CSF 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF 24 hours before and during chemotherapy (arm +/‐)
Trial: 8683249
Drug: GM‐CSF after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF after chemotherapy until day 28 or recovery of PMNs (arm ‐/+)
Trial: 8683249
Drug: GM‐CSF before,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF before, during, and after chemotherapy (arm +/+)
Trial: 1906864
Drug: Twice-daily amikacin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily amikacin (7.5 mg/kg bd) regimen (group A)
Trial: 1906864
Drug: Once-daily amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily amikacin (15 mg/kg) schedule (group B)
Trial: 6802391
Drug: Regimen using
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen using simple dietary instructions and laxatives
Trial: 29157960
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) inactivated seasonal influenza vaccine
Trial: 29157960
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) inactivated seasonal influenza vaccine
Trial: 26002596
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) plus graded exercise therapy
Trial: 21476931
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release (GXR) 1, 2, and 3 mg/day
Trial: 19066370
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 microg/d from L-selenomethionine)
Trial: 17606443
Drug: Double, intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double, intensive treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2 followed by cyclophosphamide 120 mg/kg iv plus total body irradiation 9 Gy and autologous stem cell transplantation)
Trial: 17606443
Drug: Single non‐myeloablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single non‐myeloablative treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2)
Trial: 17606443
Drug: Double, intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double, intensive treatment
Trial: 17606443
Drug: Single non‐myeloablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single non‐myeloablative treatment
Trial: 11393219
Drug: Buserelin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (40 microg in 4 doses i.v. at 12 h intervals)
Trial: 11393219
Drug: Buserelin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (40 microg in 4 doses i.v.)
Trial: 11393219
Drug: Buserelin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (4 doses of 20 microg i.v.)
Trial: 11393219
Drug: Buserelin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (3 doses of 13.3 microg at 6 h interval)
Trial: 3545418
Drug: 14-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-valent pneumococcal vaccine
Trial: 23868419
Drug: HIV care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV care and treatment services
Trial: 21948457
Drug: Hydrophilic matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic matrix based modified release formulations
Trial: 21948457
Drug: Predictions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictions of in vivo drug release
Trial: 15918525
Drug: Myung In
RxNorm normalized name: Mung bean
DrugBank: Mung bean (DB10830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myung In haloperidol (test drug)
Trial: 15918525
Drug: Peridol (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peridol (reference drug)
Trial: 10367550
Drug: Naltrexone tablet
RxNorm normalized name: naltrexone Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone tablet (50 mg) plus placebo skin patch
Trial: 10367550
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus nicotine skin patch (21 mg/24 h)
Trial: 10367550
Drug: Naltrexone tablet
RxNorm normalized name: naltrexone Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone tablet plus nicotine skin patch
Trial: 10367550
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus placebo skin patch
Trial: 8896495
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine trial participation willingness
Trial: 1854025
Drug: 60 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 micrograms/kg of oxycodone
Trial: 6340820
Drug: Levamisole 150
RxNorm normalized name: levamisole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 150 mg for three days, two weekly
Trial: 24810181
Drug: Linifanib administered
RxNorm normalized name: Linifanib
DrugBank: Linifanib (DB06080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib administered with food
Trial: 24810181
Drug: Linifanib administered
RxNorm normalized name: Linifanib
DrugBank: Linifanib (DB06080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib administered in the evening after a 2-h fast
Trial: 15907955
Drug: 2.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/kg of 100 proof (50% absolute ethanol) vodka
Trial: 10654204
Drug: Salbutamol (S),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 8 ml/kg (normal VT)
Trial: 10654204
Drug: Salbutamol (S),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 12 ml/kg (high VT)
Trial: 9456189
Drug: Epirubicin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin treatment
Trial: 6351891
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day of slow release theophylline
Trial: 28409851
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxygen and eszopiclone
Trial: 23645340
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa‐Ra group, n = 135)
Trial: 31515397
Drug: Biologic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapies
Trial: 12707578
Drug: Studies of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Studies of biologic agents
Trial: 8698440
Drug: cilazapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (5 mg twice daily)
Trial: 6089862
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (22.5 g/l)
Trial: 6089862
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (36 g/l)
Trial: 7856453
Drug: Cervical electrostimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical electrostimulation (30 minutes, twice a week for a total of 10 sessions, 18 msec duration, 100 Hz frequency)
Trial: 2510261
Drug: Rioprostil 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil 600 micrograms/daily
Trial: 2510261
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg/daily
Trial: 21234555
Drug: Desmopressin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (40 mg, nasal spray)
Trial: 11251523
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg, intramuscularly)
Trial: 19832818
Drug: Lornoxicam (LNX)
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (LNX) 8‐24 mg/day
Trial: 19832818
Drug: Diclofenac 100‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100‐150 mg/day
Trial: 15746053
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan at 80 mg/m(2)/day
Trial: 15746053
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan at 70 mg/m(2)/day
Trial: 15746053
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan (both dosages)
Trial: 15746053
Drug: Food effect
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food effect on oral irinotecan
Trial: 15746053
Drug: Oral irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irinotecan
Trial: 9678288
Drug: Irbesartan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (1 to 900 mg orally)
Trial: 7986392
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly injections of GH (group 1)
Trial: 7986392
Drug: Daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injections of GH (group 2)
Trial: 7986392
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (group 3)
Trial: 28446804
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of amlodipine (10 mg) with irbesartan (100 mg)
Trial: 28446804
Drug: Indapamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (1 mg) with irbesartan (100 mg) and amlodipine (5 mg)
Trial: 25204992
Drug: American cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American cranberry (120 mg)
Trial: 25204992
Drug: Routine prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine prophylactic therapy (control group)
Trial: 16865033
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management plus community referral for individual treatment
Trial: 12872354
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus gemcitabine at a 30-minute standard infusion (Arm A)
Trial: 12872354
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus gemcitabine at a fixed infusion rate of 10 mg/m2 per minute (Arm B)
Trial: 7539185
Drug: Phytotherapeutic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapeutic agents
Trial: 2693073
Drug: Clonidine (0.225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.225 mg/day for the first week, increased to 0.450 mg/day for the second week)
Trial: 359562
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin combined with sulfinpyrazone
Trial: 30954969
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of csDMARDs
Trial: 30954969
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of TNF inhibitors
Trial: 30954969
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of csDMARDs and TNF inhibitors
Trial: 21604206
Drug: Alcohol-based skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-based skin antiseptics (5 different solutions)
Trial: 16780618
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics (paracetamol 1 g four times a day and ibuprofen 500 mg three times a day)
Trial: 11169172
Drug: 24% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% NaCl solution
Trial: 31482765
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug (ATD) therapy
Trial: 31482765
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine (131I) therapy
Trial: 31482765
Drug: Ablative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative treatment (surgery or 131I)
Trial: 31482765
Drug: Normal thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal thyroid hormone status without thyroxine supplementation
Trial: 24553426
Drug: rs1229984 G→A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs1229984 G→A polymorphism
Trial: 17706223
Drug: IL-10 concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-10 concentration >= 1.04 pg/mL
Trial: 17706223
Drug: IL-10 concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-10 concentration < 1.04 pg/mL
Trial: 10585065
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (mitomycin C 10 mg/m2, vinblastine 6 mg/m2, cisplatin 100 mg/m2)
Trial: 6338164
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone phosphate (100 mg administered within 6 hours of the accident)
Trial: 28119041
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine monotherapy (X)
Trial: 17483009
Drug: Applephenon (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applephenon (1200 mg/d)
Trial: 17483009
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1000 mg/d)
Trial: 11593916
Drug: Naproxen 10
RxNorm normalized name: naproxen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 10 mg/kg BW bid for 2 weeks
Trial: 11593916
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and paracetamol as needed
Trial: 9589685
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day, orally for 8 weeks)
Trial: 26658899
Drug: Citrulline malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline malate (CM) 8 g dextrose + 8 g CM
Trial: 26658899
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 g dextrose)
Trial: 22451347
Drug: Echinacea angustifolia
RxNorm normalized name: Echinacea Angustifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea angustifolia extract (20 mg, 2 tablets per day)